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Role of IL-4 receptor a–positive CD41 T cells in
chronic airway hyperresponsivenessFrank Kirstein, PhD, Natalie E. Nieuwenhuizen, PhD,* Jaisubash Jayakumar, PhD, William G. C. Horsnell, PhD, and
Frank Brombacher, PhD Cape Town, South Africa, and Berlin, GermanyBackground: TH2 cells and their cytokines are associated with
allergic asthma in human subjects and with mouse models of
allergic airway disease. IL-4 signaling through the IL-4 receptor
a (IL-4Ra) chain on CD41 T cells leads to TH2 cell
differentiation in vitro, implying that IL-4Ra–responsive CD41
T cells are critical for the induction of allergic asthma. However,
mechanisms regulating acute and chronic allergen-specific TH2
responses in vivo remain incompletely understood.
Objective: This study defines the requirements for IL-4Ra–
responsive CD41 T cells and the IL-4Ra ligands IL-4 and IL-13
in the development of allergen-specific TH2 responses during the
onset and chronic phase of experimental allergic airway disease.
Methods: Development of acute and chronic ovalbumin
(OVA)–induced allergic asthma was assessed weekly in CD41 T
cell–specific IL-4Ra–deficient BALB/c mice (LckcreIL-4Ra2/lox)
and respective control mice in the presence or absence of IL-4
or IL-13.
Results: During acute allergic airway disease, IL-4 deficiency
did not prevent the onset of TH2 immune responses and OVA-
induced airway hyperresponsiveness or goblet cell hyperplasia,
irrespective of the presence or absence of IL-4Ra–responsive
CD41 T cells. In contrast, deficiency of IL-13 prevented allergic
asthma, irrespective of the presence or absence of IL-4Ra–
responsive CD41 T cells. Importantly, chronic allergic
inflammation and airway hyperresponsiveness were dependent
on IL-4Ra–responsive CD41 T cells. Deficiency in IL-4Ra–
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1852IL-17–producing T cells and, consequently, increased airway
neutrophilia.
Conclusion: IL-4–responsive T helper cells are dispensable for
acute OVA-induced airway disease but crucial in maintaining
chronic asthmatic pathology. (J Allergy Clin Immunol
2016;137:1852-62.)
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Allergic asthma is a chronic inflammatory disease of the airways
characterized by an inappropriate immune response to harmless
environmental antigens. TH2 cells regulate adaptive immune
responses to allergens, and their presence correlates with disease
symptoms in human subjects and mice.1 IL-4 plays a crucial role
in the in vitro and in vivo differentiation of TH2 cells, suggesting
major contributions for IL-4 and its receptor, IL-4 receptor a
(IL-4Ra), in regulating allergic TH2 responses.
2 However, the
initiation and maintenance of in vivo TH2 differentiation is
incompletely understood. The IL-4/IL-4Ra pathway is not essen-
tial for TH2 polarization in certain in vivo settings, and important
roles for the cytokines IL-25 and IL-33 and type 2 innate lymphoid
cells (ILC2s) have been suggested.2 Several studies described
IL-4–independent TH2 differentiation in response to allergens or
helminth infection.3,4 Other studies suggested that IL-4 signaling
is required for the expansion and maintenance of TH2 responses
after Nippostrongylus brasiliensis infection or allergen treatment
but not for the initial TH2 differentiation.
5,6
Although we and others have described IL-4Ra–independent
airway hyperresponsiveness (AHR),7,8 mouse models of allergic
asthma generally highlight the importance of IL-4, IL-5, IL-13, and
the IL-4Ra/signal transducer andactivator of transcription6 signaling
pathway for the development of allergic pathology, including airway
eosinophilia, goblet cell hyperplasia, and AHR. Mice deficient in
IL-4Ra showedabrogatedTH2cell differentiation andwereprotected
from ovalbumin (OVA)–induced allergic airway disease.9-11 IL-4Ra
is ubiquitously expressed, and we and others have successfully used
mice with cell type–specific disruptions of the Il4ra gene to identify
IL-4Ra–dependent disease symptoms mediated by airway epithelial
cells,12 smooth muscle cells,11,13 and macrophages.10 The in vivo
requirements for IL-4Ra signaling on CD41 T cells in the initiation
of allergen-specific TH2 responses remain incompletely understood.
Furthermore, it has been shown that CD41 cells and IL-4 are required
for chronic lung inflammation and AHR but might not be necessary
for chronic pathogenesis, including AHR, after acute inflammatory
responses have resolved.14-17
In the present study we used previously described LckcreIL-
4Ra2/lox mice with a CD41 T cell–specific IL-4Ra disruption18
to define whether IL-4Ra–responsive CD41 T cells and the
IL-4Ra ligands IL-4 and IL-13 are required for the initial
in vivo differentiation of an allergen-specific TH2 response and
the subsequent onset of OVA-induced allergic airway disease.
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IL-4Ra signals to sustain a TH2-type phenotype and to promote
disease pathology during chronic allergic airway inflammation.
We found that acute allergic airway disease and TH2 differentia-
tion are independent of IL-4 signaling and that IL-13 drives
airway pathology. Loss of IL-4Ra signaling on CD41 T cells
resulted in increased IL-17 production and airway neutrophilia.
Importantly, IL-4–responsive CD41 T cells promoted chronic
asthmatic disease. In conclusion, IL-4–responsive T helper cells
are dispensable for acute OVA-induced airway disease but
required to maintain chronic asthmatic pathology.
METHODS
Mice
Six- to 8-week-old female mice were used in the experiments. Generation of
LckcreIL-4Ra2/lox (C.Cg-Il4ratm1Fbb/Il4ratm2Fbb-Tg[Lck-Cre]/J) mice and IL-4R2/lox
littermateson aBALB/c backgroundwas describedpreviously.18LckcreIL-4Ra2/
lox mice and IL-4Ra2/lox littermate control mice were intercrossed with IL-4–
deficient19 or IL-13–deficient20 BALB/c mice for 9 generations. Animal proce-
dures were approved by the University of Cape Town Animal Ethics Committee.
Models of allergic airway disease
Acute OVA-induced allergic airway disease. Mice were
sensitized intraperitoneally and challenged intranasally with OVA (Sigma-
Aldrich, Aston Manor, South Africa), as previously described.10 In some
experiments mice received 0.2 mg/mouse anti–IL-17A antibody21 (clone
MM17F3, kind gift of C. Uyttenhove) or isotype-matched control antibody
by means of intraperitoneal injection on days 20 and 23.
Chronic OVA-induced allergic airway disease. Mice
were sensitized subcutaneously with 20 mg of OVA adsorbed to 0.65% alum
on days 0, 7, 14, and 21. On days 27 and 29 and then twiceweekly for 4 weeks,
mice were challenged intranasally with 20 mg of OVA in 50 mL of PBS after
achievement of anesthesia.10
AHR
Respiratory resistance and compliance of the whole respiratory system and
Newtonian resistance of the central airways were determined by means of
forced oscillation measurements with a flexiVent system (SCIREQ, Montreal,
Quebec, Canada) by using the single-compartment (‘‘snapshot’’) perturbation
or constant phase model, as previously described.11Evaluation of goblet cell hyperplasia
Periodic acid–Schiff reagent–positive goblet cells and total epithelial cell
nuclei in 5 to 8 bronchioles per lung section containing 80 to 220 epithelial
cells were counted, and the ratio was converted to a percentage.13Measurement of serum antibody levels
Total IgE and allergen-specific IgG antibody levels were measured by
means of ELISA, as described previously.11Analysis of airway and lung cell populations
Single-cell suspensions were prepared from lungs of individual mice and
stained for intracellular cytokines, as previously described.10 Bronchoalveolar
lavage (BAL)11 and lung cell composition of individual mice was
determined by means of cell-surface staining with Siglec-F–phycoerythrin
(PE), CD11c-allophycocyanin, and GR-1–fluorescein isothiocyanate (FITC)
for eosinophils, neutrophils, and alveolar macrophages; CD3-PE, CD4–
peridinin-chlorophyll-protein complex, and T1/ST2-FITC for T helper cells;
and lineage–peridinin-chlorophyll-protein complex–Cy5.5, inducible
costimulator (ICOS)–allophycocyanin, and T1/ST2-FITC for ILC2s. Flow
cytometry was performed on a FACSCalibur flow cytometer (BDBiosciences,
Erembodegem, Belgium), and data were analyzed with FlowJo version 10
software (TreeStar, Ashland, Ore). All antibodies were purchased from BD
Biosciences or eBioscience (San Diego, Calif), except T1/ST2 (MD
Bioproducts, St Paul, Minn). In some experiments BAL cells were stained
with the Rapi-Diff Stain Set (Clinical Diagnostics CC, Johannesburg, South
Africa) and analyzed based on differential cell counts, as described
previously.11Analysis of lung cytokine responses
Cytokine concentrations in lung tissue homogenate (1 mg/mL protein
concentration) were determined by means of ELISA, according to the
manufacturer’s protocols (IL-4, IL-5, and IFN-g: BD Biosciences; IL-13,
IL-17, IL-25, and IL-33: R&D Systems, Minneapolis, Minn).Statistical analysis
P values were calculated with GraphPad Prism 4 software (GraphPad
Software, San Diego, Calif) by using the nonparametric Mann-Whitney test
or Kruskal-Wallis test with the Dunn posttest. Respiratory resistance and
compliance data were analyzed with repeated-measures ANOVA with the
Bonferroni posttest. P values of .05 or less were considered significant.RESULTS
Development of OVA-induced allergic airway
disease in LckcreIL-4Ra2/lox mice
The role of IL-4Ra–responsive CD41 T cells in acute OVA-
induced allergic airway disease was investigated by using
CD41 T cell–specific IL-4Ra–deficient mice (LckcreIL-4Ra2/lox)
and IL-4Ra–responsive IL-4Ra2/lox littermate control mice
(Fig 1, A). IL-4Ra was efficiently disrupted on the cell surfaces
of CD31CD41 T cells but present on CD31CD81 T cells from
lungs of OVA-treated LckcreIL-4Ra2/lox mice, confirming
previous results (see Fig E1, A, in this article’s Online Repos-
itory at www.jacionline.org).18 Development of AHR, airway
eosinophilia, and goblet cell hyperplasia are the main
characteristics of allergic airway disease and were absent in
saline-treated LckcreIL-4Ra2/lox mice and IL-4Ra2/lox litter-
mate control animals (see Fig E1, B-D). In OVA-treated mice
respiratory resistance and compliance of the whole respiratory
system and Newtonian resistance of the central airways were
measured in response to increasing doses of inhaled methacho-
line as indicators of AHR. Importantly, AHR was not affected
by the loss of IL-4Ra expression on CD41 T cells. OVA
treatment induced increased respiratory and Newtonian
resistance and a decrease in respiratory compliance in CD41
T cell–specific IL-4Ra–deficient mice (LckcreIL-4Ra2/lox) and
IL-4Ra–expressing IL-4Ra2/lox littermate control mice, with
no significant differences between these groups (Fig 1, B).
Furthermore, efficient goblet cell hyperplasia was observed after
OVA treatment in LckcreIL-4Ra2/lox mice and littermate control
FIG 1. A, Mice received intraperitoneal (i.p.) injections of OVA/alum and intranasal (i.n.) OVA challenges.
B, Respiratory resistance, compliance (n 5 11, 12, and 14), and Newtonian resistance (n 5 5, 8, and 10) in
response to methacholine. P values are for comparison of dose-response curves by means of 2-way
repeated-measures ANOVA (means 6 SEMs). C, Goblet cell hyperplasia as indicated by arrows in
representative periodic acid–Schiff (PAS) staining and percentage of PAS-positive bronchial epithelial cells.
Aw, Airways. D, Total cell numbers in BAL fluid (n5 11, 15, and 16). E, Detection of eosinophils, neutrophils
(n 5 11, 15, and 16), alveolar macrophages, and T helper cells in BAL fluid (n 5 9, 12, and 12) by means of
flow cytometry. F,Mean fluorescence intensity (MFI) of Siglec-F–PE staining on BAL eosinophils. Data were
pooled from 2 to 3 independent experiments. Lines represent medians 6 interquartile ranges. *P < .05,
**P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
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differences between the OVA-treated groups (Fig 1, C).
A model of subcutaneous sensitization was then used to
investigate whether the route of sensitization affected our
results.10 Subcutaneous sensitization led to comparable patho-
logy with intraperitoneal sensitization in LckcreIL-4Ra2/lox
mice and IL-4Ra2/lox littermate control mice with regard to
AHR and goblet cell hyperplasia, confirming that these
parameters were not dependent on the route of sensitization
(see Fig E2 in this article’s Online Repository at www.
jacionline.org). Allergic airway inflammation is characterizedby infiltration of the lungs by eosinophils. OVA treatment led to
significant cell infiltration in the BAL, and the total number of
cells was not affected by the loss of CD41 T-cell IL-4Ra (Fig
1, D). OVA-treated CD41 T cell–specific IL-4Ra–deficient
mice (LckcreIL-4Ra2/lox) and IL-4Ra–expressing IL-4Ra2/lox
littermate control mice showed increased numbers of eosinophils,
neutrophils, and CD31CD41 T helper cells but not alveolar
macrophages in the BAL fluid (Fig 1, E) and lung tissue (see
Fig E3, A, in this article’s Online Repository at www.jacionline.
org). However, the number of eosinophils was reduced
in LckcreIL-4Ra2/lox mice compared with littermate control
FIG 2. A, Cytokine-producing CD41 T cells from lung tissue were measured by means of fluorescence-
activated cell sorting (n 5 8). B, IL-25 and IL-33 levels were measured in lung tissue homogenate by using
ELISA (n 5 9, 12, and 12). C and D, IL-33 receptor (ST2) expressing CD31CD41 T cells (Fig 2, C) and line-
age2ICOS1ST21 ILC2 populations (Fig 2, D) were detected with fluorescence-activated cell sorting (n 5 9,
12, and 12). E, Mean fluorescence intensity (MFI) of ICOS-PE staining on lung ILC2s. Data were pooled
from 2 independent experiments. F, Total IgE and OVA-specific IgE levels in blood serum were measured
by means of ELISA. Data were pooled from 3 independent experiments. (n 5 10). Lines represent
medians 6 interquartile ranges. *P < .05, **P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
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higher in the BAL fluid (Fig 1, E). Although eosinophil numbers
were increased comparedwith neutrophil numbers in IL-4Ra2/lox
littermate control mice, eosinophil and neutrophil numbers were
similar in LckcreIL-4Ra2/lox mice. BAL and lung tissue eosino-
phils in OVA-treated LckcreIL-4Ra2/lox mice and littermate
control animals showed similar upregulation of Siglec-F surface
expression, indicating an activated phenotype in both strains
(Fig 1, F, and see Fig E3, B).22,23 Together, these results demon-
strate that IL-4Ra expression on CD41T cells is not necessary for
the development of major symptoms of allergic airway disease in
mouse models of systemic OVA/alum sensitization.LckcreIL-4Ra2/lox mice maintain TH2-type cytokine
responses to OVA
Because the development of allergic airway disease is regulated
by TH2-associated cytokines, we examined the effect of a lack of
IL-4Ra responsiveness by lung CD41 T cells on their cytokine
production. OVA treatment increased numbers of CD41 T cells
producing the TH2 cytokines IL-4, IL-5, and IL-13 in OVA-
treated LckcreIL-4Ra2/lox mice and littermate control mice,
with no significant differences between these groups (Fig 2, A).
These results suggest that IL-4Ra signaling on CD41 T cells is
not required for the in vivo differentiation of IL-4–, IL-5–,
and IL-13–producing TH2 cells. Treatment with OVA also
promoted a strong IFN-g response from CD41 T cells in both
LckcreIL-4Ra2/lox mice and littermate control mice. IL-17–
producing CD41 T cells were significantly upregulated in
LckcreIL-4Ra2/lox mice compared with IL-4Ra2/lox mice,
indicating that IL-4Ra signaling on CD41 T cells inhibits the
development of TH17 responses (Fig 2,A). Analysis of lung tissuecytokines and cytokine secretion of ex vivo–stimulated lung cells
by means of ELISA confirmed a TH2-type cytokine profile in
LckcreIL-4Ra2/lox mice and IL-4Ra2/lox mice, whereas IL-17
concentrations were increased only in LckcreIL-4Ra2/lox mice
(see Fig E4 in this article’s Online Repository at www.
jacionline.org). The cytokines IL-25 and IL-33 have been impli-
cated in the development of type 2 immune responses in allergic
diseases.2 We found no significant increase in IL-25 concentra-
tions in lung tissue homogenates after OVA treatment. However,
IL-33 concentrations were upregulated in IL-4Ra2/lox and
LckcreIL-4Ra2/lox mice after OVA treatment (Fig 2,B). IL-33 sig-
nals through the T1/ST2 receptor, which is primarily expressed on
TH2 cells but not on other T-cell subtypes.
24 In agreement with the
TH2 cytokine profile in T cells, we found similar numbers of T1/
ST2-expressing CD31CD41 T cells in the lungs of IL-4Ra2/lox
and LckcreIL-4Ra2/lox mice (Fig 2, C). In addition to its role in
TH2 cell functions, IL-33 has been implicated in the differentia-
tion of ILC2s, which are able to promote type 2 immune responses
and have been linked to allergic airway inflammation.25 Allergen
challenge increased numbers of a lineage-negative ICOS1T1/
ST21 ILC2 population in the lungs of IL-4Ra2/lox and
LckcreIL-4Ra2/lox mice (Fig 2,D), which had an activated pheno-
type, as indicated by increased ICOS surface expression (Fig 2,
E).26 In conclusion, the main features of the adaptive and innate
type 2 immune response were maintained in the absence of
IL-4Ra on T cells, whereas TH17 responses were increased.Reduced IgE responses to OVA in LckcreIL-4Ra2/lox
mice
TH2-type immune responses are associated with antibody
isotype switching to IgE and IgG1, whereas IFN-g promotes
FIG 3. A, Respiratory resistance and compliance in response to methacholine (n 5 8-10). B, Goblet cell
hyperplasia as indicated by arrows in representative periodic acid–Schiff (PAS) staining and percentages
of PAS-positive bronchial epithelial cells. Aw, Airways. C, Enumeration of eosinophils, neutrophils,
lymphocytes, and macrophages in BAL fluid by differential cell counts (n 5 8). D and E, Levels of total
IgE (Fig 3, D) and OVA-specific IgG1 (Fig 3, E) in blood serum were measured by means of ELISA (n 5 8).
Data were pooled from 2 independent experiments. Lines represent means 6 SEMs. *P < .05, **P < .01,
and ***P < .001 versus PBS control. #P < .05 and ###P < .001 versus IL-4Ra2/lox. Fig 3, A, Two-way
repeated-measures ANOVA at 40 mg/mL methacholine. Fig 3, C and D, Kruskal-Wallis nonparametric test.
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creIL-4Ra2/lox mice total and
OVA-specific IgE serum concentrations were significantly
reduced compared with those in littermate control mice (Fig 2,
F). IgG responses were similar in CD41 T cell–specific
IL-4Ra–deficient mice (LckcreIL-4Ra2/lox) and littermate
control mice, with high OVA-specific IgG1 and low IgG2a and
IgG2b titers (see Fig E5 in this article’s Online Repository at
www.jacionline.org).IL-13, but not IL-4, is required for development of
OVA-mediated allergic airway disease
To clarify whether disease development in CD41 T cell–
specific IL-4Ra–deficient mice (LckcreIL-4Ra2/lox) requires
IL-4 or IL-13, we examined allergic airway responses in these
mice in the presence (LckcreIL-4Ra2/lox) or absence of IL-4
(IL-42/2LckcreIL-4Ra2/lox) or IL-13 (IL-132/2LckcreIL-4Ra2/
lox). IL-4 was not needed for OVA-induced AHR (Fig 3, A)
because IL-4–deficient mice in the presence or absence of
IL-4Ra–expressing CD41 T cells (IL-42/2IL-4Ra2/lox mice or
IL-42/2LckcreIL-4Ra2/lox) showed similar AHR responses
compared with IL-4–competent littermate control animals(IL-4Ra2/lox mice). In stark contrast, IL-13 was crucial for
OVA-induced AHR (Fig 3, A) because IL-13–deficient mice in
the presence (IL-132/2IL-4Ra2/lox) or absence (IL-132/
2LckcreIL-4Ra2/lox) of IL-4Ra–expressing CD41 T cells did
not have AHR compared with IL-13–competent littermate con-
trols (IL-4Ra2/lox). The absence of IL-4 and IL-4Ra–responsive
CD41 T cells did not significantly change the percentage of
goblet cells in the airway epithelium, whereas goblet cell hyper-
plasia was impaired in the absence of IL-13 (Fig 3, B). IL-4 and
IL-13 were required for the development of allergic airway
inflammation because IL-4 or IL-13 deficiency in LckcreIL-
4Ra2/lox mice and IL-4Ra–expressing littermate control mice
reduced eosinophilia and increased neutrophilia in the BALF
(Fig 3, C). Lymphocyte and macrophage numbers were increased
in all treatment groups compared with PBS-treated control mice,
with no significant differences between the groups (Fig 3, D). As
expected from IL-4 being responsible for isotype class-switching
to IgE, serum concentrations of IgE were drastically reduced in
OVA-challenged IL-4–deficient mouse strains (IL-42/2IL-4Ra2/
lox and IL-42/2LckcreIL-4Ra2/lox mice) compared with those
in IL-4Ra2/lox control mice (Fig 3, E). Because murine B
cells are unresponsive to IL-13, mice deficient in IL-13
FIG 4. A, Numbers of eosinophils and neutrophils in BAL fluid. B, Respiratory resistance and compliance
in response to methacholine. Data were pooled from 2 independent experiments. Lines represent
means 6 SEMs. *P < .05, **P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
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compared with IL-4Ra2/lox control mice. However, in mice
with IL-13 deficiency and IL-4Ra–unresponsive CD41 T cells
(IL-132/2LckcreIL-4Ra2/lox mice), IgE concentrations were
strikingly reduced. This was expected because CD41 T cell–
4Ra expression is required for a normal IgE response (Fig 2,
F).27 OVA-specific IgG1 concentrations were similar in
IL-4Ra2/lox, LckcreIL-4Ra2/lox, IL-132/2IL-4Ra2/lox, and
IL-132/2LckcreIL-4Ra2/lox mice but reduced in mice with an
IL-4–deficient genetic background.
In summary, the data presented here show that acute
OVA-mediated allergic airway disease and a TH2-polarized
immune response can develop independently of IL-4 and
IL-4Ra expression on CD41 T cells. Furthermore, these results
show that IL-13, but not IL-4, is mainly responsible for an allergic
phenotype.IL-17 induces neutrophilic airway inflammation in
LckcreIL-4Ra2/lox mice
OVA exposure induced a significant increase in neutrophil
counts in BAL fluid (Fig 1, E) and in IL-171CD41 T cells and IL-
17 in the lungs (Fig 2, A, and see Fig E4) of LckcreIL-4Ra2/lox
mice but not littermate control mice. IL-17 can orchestrate
neutrophil infiltration in mouse models of allergic asthma and
has been associated with the development of severe asthma and
AHR.28,29 Anti–IL-17 antibodies injected during intranasal
OVA challenge significantly reduced neutrophil numbers in
LckcreIL-4Ra2/lox mice and IL-4Ra2/lox littermate control
mice. Eosinophil numbers were not affected by anti–IL-17 anti-
body treatment (Fig 4, A). Furthermore, pulmonary resistance
and compliance in LckcreIL-4Ra2/lox and IL-4Ra2/lox mice
were not significantly altered by anti–IL-17 treatment (Fig 4,
B). Therefore increased production of IL-17 after disrupted
FIG 5. A,Mice received subcutaneous (s.c.) injections of OVA/alum followed by intranasal OVA challenges
for 5 weeks to induce chronic allergic airway disease. B, Respiratory resistance and compliance in response
to maximum (40 mg/mL) methacholine challenge. C, Eosinophils and neutrophils in BAL fluid were
analyzed by using fluorescence-activated cell sorting. Two individual experiments were performed for
days 31, 38, 45, 52, and 59. Pooled data are represented as means 6 SEMs (n 5 10-12). *P < .05,
**P < .01, and ***P < .001 versus PBS control; #P < .05, ##P < .01, and ###P < .001, IL-4Ra2/lox OVA versus
LckcreIL-4Ra2/lox OVA, Mann-Whitney nonparametric test.
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neutrophilia but did not contribute to the development of AHR.IL-4Ra–responsive CD41 T cells are required to
sustain chronic AHR and eosinophilic lung
inflammation
Having defined the roles of IL-4–, IL-13–, and IL-4Ra–
responsive CD41 T cells in the onset of OVA-mediated allergic
asthma, we investigated the role of IL-4Ra–responsive CD41 T
cells in maintaining chronic allergic airway disease. Mice
received systemic OVA sensitization followed by intranasal chal-
lenges over 5 consecutive weeks (Fig 5, A).10 Baseline values for
respiratory resistance and compliance measured before metha-
choline challenge were not affected in LckcreIL-4Ra2/lox and
IL-4Ra2/lox mice after 5 weeks of chronic airway exposure to
allergens, indicating that chronic OVA exposure did not affect
general lung function (see Fig E6, A, in this article’s Online
Repository at www.jacionline.org). AHR in response to
methacholine did not significantly change during the 5-week
course of allergen challenge in OVA-treated IL-4Ra2/lox mice
(Fig 5, B, and see Fig E7 in this article’s Online Repository at
www.jacionline.org). However, AHR was significantly reduced
in LckcreIL-4Ra2/lox mice from day 45 onward and decreased
to levels similar to those in PBS-treated control groups by day
52 (Fig 5, B, and see Fig E7). Chronic airway inflammation was
assessed by measuring numbers of BAL cells. BAL fluid eosino-
phil numbers continuously decreased over the 5-week period of
allergen exposure in LckcreIL-4Ra2/lox and IL-4Ra2/lox mice
(Fig 5, C). However, in CD41 T cell–specific IL-4Ra–deficient
LckcreIL-4Ra2/lox mice, airway eosinophilia was significantly
reduced at every time point compared with that in littermate
control mice and was resolved by day 52 (Fig 5, C). Surface
expression of the activation marker Siglec-F on eosinophils was
not significantly different in LckcreIL-4Ra2/lox and IL-4Ra2/lox
mice until day 59, when eosinophils were hard to detect in
LckcreIL-4Ra2/lox mice (see Fig E6, B). Airway neutrophilia
was significantly increased in LckcreIL-4Ra2/lox mice compared
with that in IL-4Ra2/lox mice after the first week of allergenchallenge, and similar numbers were observed afterward in
LckcreIL-4Ra2/lox mice and IL-4Ra2/lox littermate control mice
(Fig 5, C). Numbers of alveolar macrophages did not differ
between LckcreIL-4Ra2/lox mice and IL-4Ra2/lox littermate
control mice or change significantly over the course of allergen
challenge (see Fig E6, C). Together, these results demonstrate
that IL-4Ra expression on T cells is critical for maintaining the
hallmarks of allergic airway disease, such as AHR and airway
inflammation, in response to chronic allergen exposure.Type 2–specific cytokine responses are maintained
after impairment of IL-4Ra responsiveness in CD41
T cells during chronic allergic asthma
OVA treatment induced TH2 cytokine production by CD4
1 T
cells from lungs independently of IL-4Ra responsiveness during
chronic allergen challenge (Fig 6, A). Numbers of CD41 T cells
producing the TH2 cytokines IL-4, IL-5, and IL-13 were not
significantly different in CD41 T cell–specific IL-4Ra–deficient
LckcreIL-4Ra2/lox mice and IL-4Ra–expressing IL-4Ra2/lox
littermate control mice throughout the course of OVA challenges.
Numbers of IFN-g– or IL-10–producing CD41 T cells were
similar in control IL-4Ra2/lox mice and LckcreIL-4Ra2/lox
mice. Of note, the numbers of IL-17–producing CD41 T cells
were higher in LckcreIL-4Ra2/lox mice throughout the course of
allergen challenge (Fig 6, A). Total IgE and OVA-specific IgE
serum concentrations were increased in IL-4Ra2/lox compared
with LckcreIL-4Ra2/lox mice and peaked on day 45 (Fig 6, B).
OVA-specific IgG1 antibodies were detected at the highest
concentrations on day 45, with no significant differences between
IL-4Ra2/lox and LckcreIL-4Ra2/lox mice (see Fig E8 in this
article’s Online Repository at www.jacionline.org). Levels of
the type 1–associated antibodies IgG2a and IgG2b were increased
in LckcreIL-4Ra2/lox mice compared with those in littermate
control mice (see Fig E8). In conclusion, impairment of IL-4Ra
responsiveness by CD41 T cells during chronic disease leads to
reduced IgE responses and enhanced TH17 cytokine responses
but does not impair TH2 cytokine (IL-4, IL-5, and IL-13)
production.
FIG 6. A, Cytokine-producing CD41 T cells from lung tissue were measured by using fluorescence-activated
cell sorting. B, Total IgE and OVA-specific IgE levels in blood serum were measured by using ELISA. Specific
antibody response is represented as OD values at 1:3 serum dilution. Data were pooled from 2 individual
experiments on days 31, 38, 45, 52, and 59 and represented as means 6 SEMs. IL-4Ra2/lox PBS, n 5 5 to 8;
IL-4Ra2/lox OVA and LckcreIL-4Ra2/lox OVA, n 5 7 to 8. *P < .05, **P < .01, and ***P < .001 versus PBS
control. #P< .05and##P< .01, IL-4Ra2/loxOVAversusLckcreIL-4Ra2/loxOVA,Kruskal-Wallisnonparametric test.
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Allergic asthma is considered to be driven by allergen-specific
TH2 immune responses, and CD4
1 T cells are an essential
source of TH2 cytokines. According to the paradigm for the
development of TH2 immunity, the IL-4/IL-4Ra signaling
pathway on CD41 T cells is of key importance for TH2 cell
differentiation and subsequently for allergic asthma. However,
mechanisms of in vivo TH2 differentiation and the role of
IL-4Ra in mouse models are not fully understood, and we and
others have demonstrated that TH2 responses can develop in theabsence of the canonical IL-4/IL-4Ra–mediated pathway of
TH2 differentiation.
4,5,30-32
Our previous studies with CD41 T cell–specific IL-4Ra–
deficient LckcreIL-4Ra2/lox mice in infectious disease models
indicated critical contributions of IL-4Ra1 T cells to TH2-
mediated lung pathology.33-35 However, our previous studies on
mouse models of allergic dermatitis or anaphylaxis indicated
that TH2-type immune responses to allergen exposure can
develop in the absence of IL-4 and IL-4Ra–expressing CD41 T
cells.36,37 The present study demonstrates that IL-4–responsive
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airway disease pathology and that TH2-type immunity to OVA de-
velops in the absence of IL-4 signaling. Furthermore, the loss of
IL-4Ra signaling on CD41 T cells resulted in increased IL-17
production. IL-17 can orchestrate neutrophil infiltration in mouse
models of allergic asthma, whereas IL-5 recruits eosinophils.
Accordingly, we found similar numbers of neutrophils and eosin-
ophils in the presence of IL-5 and IL-17 in LckcreIL-4Ra2/lox
mice.
It is now appreciated that other cytokines, such as IL-25 and IL-
33, can induce in vivo differentiation of TH2 cells.
2 We found IL-
33 and numbers of CD41 T cells expressing the IL-33 receptor
T1/ST2 to be upregulated on airway exposure to OVA, irrespec-
tive of the presence of IL-4Ra–responsive CD41 T cells. IL-33
can induce production of IL-5 and IL-13 in CD41T cells indepen-
dently of IL-4 in vitro,38 and IL-33–primed dendritic cells induce
the development of TH2 cells, which are crucial for allergic
airway inflammation.39 Furthermore, IL-25 and IL-33 have
been associated with expansion of ILC2s in allergic responses.
A recent study found that these cells drove the initiation of
allergic airway inflammation in response to the protease allergen
papain and mediated TH2 responses independently of IL-4.
40 We
found similar numbers of activated ILC2s in mice lacking IL-4–
responsive T cells and in littermate control mice, which might
explain the IL-4–independent development of TH2 responses.
However, a recent study in a similar model of OVA-induced
allergic asthma showed that ILC2s were dispensable in the devel-
opment of TH2 and, subsequently, the development of allergic
airway inflammation responses.41 Together with the results
from our study, this indicates that systemic sensitization with
OVA induces a strong TH2-driven allergic response and ILC2
activation in the absence of the canonical IL-4–driven pathway
of TH2 differentiation.
CD41 T cells are required for initiation of allergic airway
inflammation42 and development of chronic asthmatic pathology
in mouse models.43 Therefore we wanted to investigate whether
IL-4Ra expression by CD41T cells contributes to chronic airway
inflammation and disease pathology. Strikingly, disruption of IL-
4Ra expression on CD41T cells was sufficient to abrogate persis-
tent AHR after 2 weeks of chronic OVA exposure. Our results and
previous studies44,45 showed that chronic AHR did not correlate
with the degree of eosinophilic airway inflammation or activation
status of lung eosinophils. IL-4Ra2/lox mice sustained AHR at a
high magnitude despite a decrease in pulmonary eosinophil
numbers. We found that IL-4 signaling on CD41 T cells contrib-
uted to the maintenance of chronic airway eosinophilia because in
LckcreIL-4Ra2/lox mice eosinophilia was completely resolved
after 5 weeks of OVA exposure. Despite this striking reduction
in airway eosinophilia and AHR, LckcreIL-4Ra2/lox mice still
presented with IL-5 and IL-13 cytokine-producing T cells in the
lung. This would suggest that IL-4Ra expression on CD41T cells
contributes to chronic eosinophilia and AHR through factors
other than chronic TH2-type cytokine production, including
IL-5 and IL-13. Chronic AHR can be sustained independently
of IL-13 and might not correlate with the presence of TH2
cytokine–producing T helper cells.15,46We did not find significant
differences in CD41 T cells producing either IFN-g or IL-10,
cytokines associated with TH1 or regulatory T-cell responses,
respectively. However, IL-17–producing T-cell counts were
constantly increased in CD41 T cell–specific IL-4Ra–deficient
(LckcreIL-4Ra2/lox) mice. IL-17 has been found to contribute tothe development of allergic asthma but to downregulate
established allergic airway inflammation and reduce pulmonary
eosinophil recruitment and AHR in mouse models of
OVA-induced asthma.47 This might explain the reduced numbers
of eosinophils in the presence of IL-5–producing CD41 T cells in
LckcreIL-4Ra2/lox mice in which lung IL-17 levels were
significantly increased.
In our study IL-17 neutralization in the acute phase of allergic
airway disease did not significantly alter AHR development but
reduced numbers of BAL neutrophils significantly. In the chronic
phase AHR and airway eosinophilia was resolved faster in
LckcreIL-4Ra2/lox mice in the presence of high numbers of
IL-17–producing CD41 T cells. Therefore our study does not
support an important role for IL-17 in the development of acute
AHR, but we cannot rule out a protective rule of IL-17 during
the chronic phase of the disease. On the other hand, TH17 cells
are upregulated in the lungs of asthmatic patients and linked to
severe clinical phenotypes, such as neutrophilic steroid-resistant
asthma, and are often considered to be detrimental in allergic
airway disease.29
We found a significant reduction in serum concentrations of
total and OVA-specific IgE in LckcreIL-4Ra2/lox mice in the acute
phase and during chronic allergen challenge. An acute allergic
airway response can develop independently of IgE in mice, but
mast cells and FcεRI contribute to the development of AHR in
chronic asthma through antibody-mediated mechanisms.48-50
Therefore it is possible that the reduced AHR in
LckcreIL-4Ra2/lox mice is due to reduced IgE antibody titers
affecting mast cell–mediated responses.
This study extends our understanding of the regulation of acute
and chronic allergic airway responses and TH2-type immune
responses. We provide substantial evidence for differential re-
quirements of IL-4Ra–responsive CD41 T cells during the acute
and chronic phases of allergic airway disease. IL-4Ra expression
on CD41 T cells plays a major role in the pathogenesis of chronic
asthma and the regulation of allergen-specific TH17 responses,
whereas acute asthmatic pathology and TH2 responses developed
in the absence of IL-4Ra–responsive CD41 T cells and IL-4.
The molecular mechanisms behind IL-4–independent TH2
differentiation in response to OVA and AHR during chronic
allergic airway responses remain to be determined.
We thank Catherine Uyttenhove and Jacques van Snick, Ludwig Institute
for Cancer Research, Brussels, for kindly providing anti–IL-17 antibody and
isotype control.
Key messages
d OVA-mediated acute allergic airway disease is indepen-
dent of IL-4–promoted TH2 differentiation but dependent
on IL-13 functions.
d Loss of IL-4Ra signaling on CD41 T cells results in
increased IL-17 production and airway neutrophilia.
d OVA-mediated chronic asthmatic disease is promoted by
IL-4–responsive CD41 T cells.
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Analysis of in vitro cytokine production
For analysis of ex vivo cytokine production, single-cell suspensions from
individual lungs ofOVA-treated and controlmicewere incubated for 120 hours
at 4 3 106 cells/mL in 200 mL of IMDM (Gibco, Loughborough, UnitedKingdom)/10% FCS (Delta, Johannesburg, South Africa) in 96-well plates.
Cells were stimulated with OVA (100 mg/mL), and supernatants were
collected after 120 hours. Concentrations of IL-5, IFN-g (BD Biosciences),
and IL-17 (R&D Systems) were measured by using sandwich ELISA assays,
according to the manufacturer’s protocol.
FIG E1. A, Expression of IL-4Ra on CD41 or CD81 T cells from lungs of OVA-treated IL-4Ra2/lox and LckcreIL-
4Ra2/lox mice. GM, Geometric mean. B, LckcreIL-4Ra2/lox mice and littermate control mice received
intraperitoneal (i.p.) injections of PBS/alum and intranasal PBS challenges. Respiratory resistance and
compliance in response to methacholine (n5 6). C, Eosinophils and neutrophils in BAL fluid were analyzed
by using fluorescence-activated cell sorting (n 5 6). D, Representative periodic acid–Schiff staining of lung
sections. Aw, Airways. Bars represent means 6 SEMs. Kruskal-Wallis nonparametric test.
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FIG E2. A, Mice received subcutaneous (s.c.) injections of OVA/alum and intranasal OVA challenges to
induce allergic airway disease. B, Airway resistance and compliance in response tomethacholine. C, Airway
mucus secretion and goblet cell hyperplasia as indicated by arrows in representative periodic acid–Schiff
staining. Aw, Airways. Data were pooled from 2 independent experiments. Bars represent means 6
SEMs. *P < .05, **P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
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FIG E3. A, Detection of eosinophils, neutrophils, alveolar macrophages,
and T helper cells in digested lung tissue (n 5 9, 12, and 12) by using
flow cytometry. B, Mean fluorescence intensity (MFI) of Siglec-F–PE
staining on eosinophils (n 5 9, 12, and 12). Data were pooled from 2
independent experiments. Bars represent means 6 SEMs. *P < .05,
**P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
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FIG E4. A, Levels of TH2-, TH1-, and TH17-associated cytokines weremeasured in lung tissue homogenate by
using ELISA (n5 9, 12, and 12). B, IL-5, IFN-g, and IL-17 levels were measured in cell-culture supernatants of
ex vivo lung cells stimulated with OVA (n 5 4, 7, and 7). Data are from one of 2 representative experiments.
Lines represent medians 6 interquartile ranges. *P < .05, Kruskal-Wallis nonparametric test.
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FIG E5. OVA-specific IgG levels in blood serum were measured by using ELISA. Data were pooled from 3
independent experiments. A, n 5 10. B, n 5 9, 14, and 12. Bars represent means 6 SEMs. Kruskal-Wallis
nonparametric test.
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FIG E6. A, Baseline respiratory resistance and compliance before methacholine challenge. B, Mean
fluorescence intensity (MFI) of Siglec-F–PE staining on BAL eosinophils. C, Alveolar macrophages in BAL
fluid were analyzed by using fluorescence-activated cell sorting. Two individual experiments were
performed for days 31, 38, 45, 52, and 59. Pooled data were represented as means 6 SEMs (n 5 10-12).
*P < .05, Mann-Whitney nonparametric test.
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FIG E7. A, Dose-response curves for respiratory resistance in response to methacholine at individual time
points during chronic OVA challenge. B, Dose-response curves for respiratory compliance in response to
methacholine at individual time points during chronic OVA challenge. Pooled data were from 2 experiments
for each time point. Data are shown as means 6 SEMs (n 5 8-12). **P < .01 and ***P < .001 versus PBS
control, repeated-measures ANOVA.
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FIG E8. IgG isotypes in blood serum were measured by using ELISA at indicated serum dilutions. Pooled
data from 2 individual experiments on days 31, 38, 45, 52, and 59 were represented as means 6 SEMs.
IL-4Ra2/lox PBS, n 5 5 to 8; IL-4Ra2/lox OVA and LckcreIL-4Ra2/lox OVA, n 5 7 to 8. *P < .05, **P < .01, and
***P < .001 versus PBS control, Kruskal-Wallis nonparametric test.
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